Abstract
A variety of chemotherapeutic agents induce cell death via apoptosis. We had shown previously that gemcitabine (2′,2′-difluorodeoxycytidine) induced an atypical apoptosis in BG-1 human ovarian cancer cells; therefore, further studies were conducted to characterize more precisely gemcitabine-induced apoptosis in BG-1 cells compared to a general inducer of apoptosis, staurosporine. BG-1 cells exposed to 0.5, 1.0 and 10 μM gemcitabine for 8 h, or staurosporine (1.0 μM) for 6 h, exhibited high molecular weight DNA fragmentation (50 kbp); however, only staurosporine treatment produced internucleosomal DNA fragments (200 bp) in a laddered pattern on the agarose gel. Staurosporine (1.0 μM) rapidly induced phosphatidylserine plasma membrane translocation that increased linearly with time as measured by annexin V-FITC binding, and similar kinetics were observed for caspase activation by staurosporine in BG-1 cells. In contrast, 10 μM gemcitabine increased phosphatidylserine expression in a small fraction of cells (5–10%) vs. untreated controls over the course of 48 h and significant caspase activity was detected within 12 h of drug exposure. Time-lapse video microscopy of BG-1 cells exposed to 1.0 μM staurosporine or 10 μM gemcitabine for up to 72 h showed that the morphologic changes and kinetics of cell death induced by these agents differed significantly. We also evaluated the apoptosis induced by paclitaxel (a mitotic poison) and cisplatin (an agent not dependent on cell cycle functions) in BG-1 cells by these methods because these drugs are used clinically to treat ovarian cancer. Our findings demonstrate that the kinetics of apoptotic cell death induced by gemcitabine and other chemotherapeutic agents should be taken into account when designing treatment strategies for ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3–10.
Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993; 68: 52–56.
Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995; 22: 19–25.
Bouffard DY, Momparler RL. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 1995; 19: 849–856.
Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs intoDNAis a critical event. Cancer Chemother Pharmacol 1995; 36: 181–188.
Cartee L, Kucera GL. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 1998; 41: 403– 412.
Allouche M, Bettaieb A, Vindis C, Rousse A, Grignon C, Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene 1997; 14: 1837–1845.
Srinivasan A, Foster LM, Testa MP, et al. Bcl-2 expression in neural cells blocks activation of ICE/CED-3 family proteases during apoptosis. J Neurosci 1996; 16: 5654–5660.
Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996; 271: 31075– 31085.
Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC. Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 1997; 45: 923–934.
Fornari FA Jr, Jarvis WD, Grant S, et al. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 1994; 5: 723–733.
Otto AM, Paddenberg R, Schubert S, Mannherz HG. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996; 122: 603–612.
Ozols RF. Ovarian cancer, part II: treatment. Curr Probl Cancer 1992; 16: 61–126.
Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol 1997; 8: 1045–1048.
Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995; 82: 349–352.
Kumar S. The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol 1997; 29: 393–396.
Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Brit Med Bull 1997; 53: 491–508.
Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545–1556.
Frey T. Correlated flow cytometric analysis of terminal events in apoptosis reveals the absence of some changes in some model systems. Cytometry 1997; 28: 253–263.
Falcieri E, Martelli AM, Bareggi R, Cataldi A, Cocco L. The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem Biophys Res Commun 1993; 193: 13–18.
Jarvis WD, Turner A, Grant S. The protein kinase C inhibitor staurosporine potentiates 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 and U937 leukemia cells, resulting in synergistic antileukemic effects. Proc Am Assoc Cancer Res 1993; 35: 189.
McNeil C. Ovarian cancer: latest gains establish new battle fronts. J Natl Cancer Inst 1995; 87: 871–873.
Hansen HH, Eisenhauer EA, Hansen M, et al. New cytostatic drugs in ovarian cancer. Ann Oncol 1993; 4: 63–70.
Oberhammer F, Wilson JW, Dive C, et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993; 12: 3679–3684.
Pulkkinen JO, Elomaa L, Joensuu H, et al. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 1996; 122: 214–218.
Porter AG, Ng P, Janicke RU. Death substrates come alive. Bioessays 1997; 19: 501–507.
Engeland van M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger, CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1–9.
Halicka HD, Seiter K, Feldman EJ, et al. Cell cycle specificity of apoptosis during treatment of leukaemias. Apoptosis 1997; 2: 25–39.
Eastman A. Apoptosis: a product of programmed and unprogrammed cell death. Toxicol Appl Pharmacol 1993; 121: 160– 164.
Rouquet N, Carlier K, Briand P, Wiels J, Joulin V. Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes. Biochem Biophys Res Commun 1996; 229: 27–35.
Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to anti-tumor effect of paclitaxel. J Natl Cancer Inst 1996; 88: 1308– 1314.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cartee, L., Kucera, G.L. & Willingham, M.C. Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin. Apoptosis 3, 439–449 (1998). https://doi.org/10.1023/A:1009614703977
Issue Date:
DOI: https://doi.org/10.1023/A:1009614703977